)
Spermosens (SPERM) investor relations material
Spermosens Status update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Clinical and technical progress
Generation 3 study aims to establish a statistically significant correlation between sperm binding strength and fertilization outcomes in unexplained infertility cases.
Success would be identifying a measurable parameter distinguishing poor from good sperm, which is highly sought by potential partners.
Additional clinical validation at external sites is being actively pursued, with preparations ongoing but not expected to start this year.
Regulatory and quality validation work is required before commercial launch, with possible phased market entry depending on local requirements.
ISO certification audit was passed with no remarks, supporting readiness for regulatory processes.
Commercial and partnership developments
Partnership discussions have broadened and deepened, with memoranda of understanding and confidential agreements in place with several companies in the US, Europe, and Japan.
Ambition remains to sign at least one commercial or licensing agreement by the second half of 2026, with a possibility of earlier deals.
Multiple business models are under consideration, including outright licensing and models involving regulatory or manufacturing commitments.
Manufacturing and supply readiness is being developed in parallel to ensure scalability and meet partner expectations.
Partners are sought for their ambition, growth, and sales capabilities, with both large and agile innovative companies considered relevant.
Market potential and competitive landscape
Feedback from global partners indicates strong market interest if clinical value is proven, with potential pricing of several hundred dollars per test in the US and over €100 in Europe.
No direct competitors currently offer a product measuring sperm's ability to bind and fertilize the egg; the product is positioned as an extension to existing diagnostic tools.
Initial market introduction may target smaller segments, expanding as more evidence is gathered.
- Clinical study recruitment surpassed expectations; capital facility secured to support commercialization.SPERM
Q2 2026 - JUNO-Checked Gen 3 completed, clinical validation underway, and key partnerships advanced.SPERM
Q1 2026 - Clinical validation and licensing targeted for 2026; strong partner interest and cost control.SPERM
Status update - Patent wins, clinical validation, and strong cash position set stage for 2026 commercialization.SPERM
Q4 2025 - Clinical validation, patent wins, and strong liquidity support next-gen product launch plans.SPERM
Q3 2025 - Clinical validation and new funding support product development and market entry.SPERM
Q2 2025 - Clinical study progress, strategic partnerships, and capital raises drive Spermosens' 2024 outlook.SPERM
Q3 2024 - Operating loss narrows, but liquidity shortfall drives urgent capital raise and US expansion.SPERM
Q2 2024 - Positive clinical results and new funding position Spermosens for growth in fertility diagnostics.SPERM
Q1 2025
Next Spermosens earnings date
Next Spermosens earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)